Ado-Trastuzumab Emtansine

Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.

Also Known As:

Networked: 626 relevant articles (94 outcomes, 144 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Krop, Ian E: 22 articles (10/2022 - 06/2010)
2.	Girish, Sandhya: 22 articles (01/2019 - 06/2010)
3.	Hurvitz, Sara A: 14 articles (01/2022 - 09/2012)
4.	Burris, Howard A: 14 articles (11/2019 - 06/2010)
5.	Wang, Bei: 13 articles (10/2020 - 05/2012)
6.	Winer, Eric P: 10 articles (10/2022 - 09/2012)
7.	Tamura, Kenji: 10 articles (09/2022 - 01/2015)
8.	Modi, Shanu: 10 articles (01/2022 - 06/2010)
9.	Sliwkowski, Mark X: 10 articles (01/2018 - 11/2008)
10.	Harbeck, Nadia: 9 articles (10/2022 - 01/2014)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 10/24/2023 - "Here, we report a case of HER2 positive metastatic breast cancer on a woman in her late 30s, with remission for over 3 years under second-line treatment with ado-trastuzumab emtansine, with no significant toxicity and good tolerability. " 01/01/2017 - "This descriptive analysis of final overall survival in the EMILIA trial shows that trastuzumab emtansine improved overall survival in patients with previously treated HER2-positive metastatic breast cancer even in the presence of crossover treatment. " 08/01/2018 - "Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance for Better Outcome in Patients with HER2-Positive Metastatic Breast Cancer." 12/15/2017 - "The ADCs with galactoside linkers demonstrated superior therapeutic efficacy in mice compared to the marketed trastuzumab emtansine used for the treatment of breast cancer." 01/01/2021 - "The study showed that a treatment called trastuzumab emtansine (shortened to T-DM1) improved the survival of patients with a particular type of breast cancer, known as HER2+ metastatic breast cancer (mBC). "
2.	Neoplasms (Cancer) 05/01/2023 - "Using a drug conjugated anti-HER2 antibody (trastuzumab emtansine) in a mouse PCa xenograft model delayed metastatic tumor growth, suggesting approaches that target HER2-high cells may be beneficial in treating PCa. " 11/01/2019 - "This treatment subprotocol was designed to screen for potential signals of efficacy of ado-trastuzumab emtansine (T-DM1) in HER2-amplified histologies other than breast and gastroesophageal tumors. " 11/01/2021 - "In vivo xenograft studies indicated that the AJICAP-ADCs displayed significant tumor inhibition comparable to benchmark ADC Kadcyla. " 12/01/2018 - "Our objective was to determine correlations between the tumor uptake and T/B ratios for 89Zr-labeled T-DM1 (89Zr-DFO-T-DM1) in mice with human BC xenografts by microPET/CT and biodistribution studies with HER2 expression and response to treatment with trastuzumab-DM1 (T-DM1). " 11/01/2013 - "Several phase II and III studies are under way investigating trastuzumab emtansine in combination with other regimens in patients with HER2-positive cancers. "
3.	Adenocarcinoma 02/01/2020 - "Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study." 08/01/2021 - "Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]." 11/01/2019 - "Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q." 01/01/2017 - "In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction). " 04/01/2023 - "A Case Report on the Efficacy of Trastuzumab Emtansine in a Patient With Human Epidermal Growth Factor Receptor 2 Exon 20-Mutated Adenocarcinoma of the Lung."
4.	Lung Neoplasms (Lung Cancer) 01/01/2018 - "Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial." 01/01/2018 - "Conclusion Ado-trastuzumab emtansine is an active agent in patients with HER2-mutant lung cancers. " 04/01/2015 - "Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer." 11/12/2020 - "In vitro study showed that the level of HER2 expression had no correlation with the sensitivity to EGFR-TKI, erlotinib but showed some correlation with HER2-inhibitor, ado-trastuzumab emtansine (T-DM1) in multiple EGFR-mutant lung cancer cell lines. " 01/01/2018 - "We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial. "
5.	Stomach Neoplasms (Stomach Cancer) 07/28/2011 - "Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer." 10/01/2019 - "Most patients with HER2-positive breast or gastric cancer exhibit primary or acquired resistance to trastuzumab emtansine (T-DM1), and such patients may have limited therapeutic options. " 01/01/2018 - "Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)." 12/01/2017 - "Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)." 01/01/2016 - "In vitro data on this hertuzumab-vcMMAE has exerted much stronger antitumor activity compared to trastuzumab-DM1 in HER2 positive gastric cancer cells. "

Related Drugs and Biologics

1.	Trastuzumab (Herceptin)
2.	Immunoconjugates (Immunoconjugate)
3.	pertuzumab
4.	human ERBB2 protein
5.	Lapatinib (GW572016)
6.	Capecitabine (Xeloda)
7.	trastuzumab deruxtecan
8.	ErbB Receptors (EGF Receptor)
9.	taxane
10.	Brentuximab Vedotin

Related Therapies and Procedures

1.	Therapeutics
2.	Neoadjuvant Therapy
3.	Drug Therapy (Chemotherapy)
4.	Radiotherapy
5.	Drug Tapering